Format

Send to

Choose Destination
Front Oncol. 2014 Sep 15;4:248. doi: 10.3389/fonc.2014.00248. eCollection 2014.

The management of brain metastases in non-small cell lung cancer.

Author information

1
Division of Medical Oncology, Department of Oncology, McGill University Health Centre , Montreal, QC , Canada.
2
Division of Radiation Oncology, Department of Oncology, McGill University Health Centre , Montreal, QC , Canada.

Abstract

Brain metastases (BM) are a common and lethal complication of non-small cell lung cancer (NSCLC), which portend a poor prognosis. In addition, their management implies several challenges including preservation of neurological and neurocognitive function during surgery or radiation-therapy, minimizing iatrogenic complications of supportive medications, and optimizing drug delivery across the blood-brain barrier. Despite these challenges, advancements in combined modality approaches can deliver hope of improved overall survival and quality of life for a subset of NSCLC patients with BM. Moreover, new drugs harnessing our greater understanding of tumor biology promise to build on this hope. In this mini-review, we revised the management of BM in NSCLC including advancements in neurosurgery, radiation therapy, as well as systemic and supportive therapy.

KEYWORDS:

brain metastases; chemotherapy; lung cancer; radiation therapy; stereotactic radiosurgery; surgery; targeted therapy

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center